Preclinical research highlights the use of exosomes derived from mesenchymal stem cells, suggesting a novel therapy for chronic respiratory disease BPD.
Bronchopulmonary dysplasia (BPD) is the most common chronic respiratory disease in premature infants and affects their survival rate and quality of life. There are no no reliable treatments for the prevention or treatment of BPD. The emergence of mesenchymal stem cells (MSCs) therapies, has brought new hope for the treatment of BPD. Research has shown that physiological improvements in the lungs of patients with BPD after MSC therapy and the therapeutic mechanism of action may be paracrine. The therapeutic vector in the MSC secretome comprises exosomes who have advantages such as low immunogenicity, stability, and ease of crossing the blood‒brain barrier. In the future, exosomes may become the preferred treatment for BPD in clinical settings. Here, we review the progress of preclinical research on the use of mesenchymal stem cell-derived exosomes (MSC-Exos) in the treatment of BPD as a promising treatment option.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: